Health System

Katharine Simon, PhD, clinical pediatric psychologist, and postdoctoral researcher, Sleep and Cognition Lab, UC Irvine, explains the influence of the autonomic nervous system on body functions and recommendations for patients experiencing autonomic imbalance and sleep dysregulation.

Shalini Paruthi, MD, medical codirector, St. Luke’s Hospital, Sleep Medicine and Research Center, and cochair of SLEEP 2021, highlights discussion topics that will address best practices for evaluating, diagnosing, and treating common sleep disorders.

Michael Thorpy, MD, director of the Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine, discusses aspects of the Idiopathic Hypersomnia Severity Scale, and how it fared in measuring symptoms of idiopathic hypersomnia compared with traditional scales.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The authors report an approach of outpatient clinic workflow reorganization utilizing simple, inexpensive measures to improve patient engagement and experience in addition to providing a safe setting for patients for clinic visits in the wake of COVID-19.

An initiative launched with the intent to deliver equitable cancer care improved the enrollment rates of Black participants in cancer clinical trials by focusing on community outreach and engagement.

Rebecca Spencer, PhD, professor, Department of Psychological and Brain Sciences, University of Massachusetts Amherst, and co-chair of SLEEP 2021, highlights takeaways from this year’s meeting and discussions she’s looking forward to.

Camille Hertzka, vice president and head of oncology, US Medical, AstraZeneca, speaks on how the OlympiA findings may warrant greater need of genetic testing for BRCA mutation and the efficacy of olaparib by patient subgroup.

FDA and ASPR issue policy recommendations to reform US pharmaceutical supply chains; insurer coverage implications of the newly approved therapy in Alzheimer disease; Apple announces new health data sharing features.

The FDA approves a new drug for Alzheimer disease; COVID-19–related hospitalization rates are on the rise among adolescents; efforts to address racism, discrimination, and implicit bias in health care; the United States will send 1 million Johnson & Johnson COVID-19 vaccines to Mexico cities along the border and resorts.

Shalini Paruthi, MD, medical codirector, St. Luke’s Hospital Sleep Medicine and Research Center, and cochair of SLEEP 2021, discusses the sessions and discussions she is looking forward to at this year's meeting.

Camille Hertzka, vice president and head of Oncology, US Medical, AstraZeneca, discussed updated findings of the PACIFIC trial that indicated a third of patients with unresectable non-small cell lung cancer are stable at 5 years.

The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Variances between sex and age were found among patients with chronic obstructive pulmonary disease (COPD) with a viral infection who visited the emergency department (ED) visit or were hospitalized, highlighting the role that these factors play.

Davey Daniel, MD, hematology/medical oncology specialist, Tennessee Oncology, discusses findings of an abstract presented at ASCO 2021 showing a lower total cost of care paid by Medicare for episodes of care for patients in the Oncology Care Model (OCM) enrolled in clinical trials vs those receiving routine care.

In this white paper from Humana, the authors discuss how the aftermath of COVID-19 will require the frequent use of screeners and tools to assess changes in health status, including health-related quality of life and social health. Taking into account the results that matter most to patients will be key to improving health outcomes.

On the eve of the 40th anniversary of the CDC’s first report on what would become known as HIV/AIDS, Perry N. Halkitis, PhD, MS, MPH, sends out an urgent call to continue this fight and rededicate resources to finding a cure.

Patients with acute myeloid leukemia (AML) who relapse after first-line treatment face a substantial health care resource utilization (HCRU) and cost burden, according to a poster presented at Virtual ISPOR 2021.

Results from Sharecare's Community Well-Being Index show Massachusetts was the healthiest state in 2020 while Mississippi ranked last.

A higher risk of COVID-19–related mortality was found among hospitalized patients with Parkinson disease (PD) than in the general population. Overall inpatient mortality of those with PD was also significantly higher in 2020 than in the year prior.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research, as well as implications for future studies.

An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.

Mark Trusheim, MS, BS, strategic director at the NEW Drug Development ParadIGmS program and visiting scientist at Massachusetts Institute of Technology, explains factors involved when considering whether a therapy would be suitable for performance-based contracting.